Details
Stereochemistry | ACHIRAL |
Molecular Formula | C7H7N6.Na |
Molecular Weight | 198.1604 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].C1CC2=C(C1)C(=NN2)C3=NN=N[N-]3
InChI
InChIKey=WAEMBJUTNFWNNK-UHFFFAOYSA-N
InChI=1S/C7H7N6.Na/c1-2-4-5(3-1)8-9-6(4)7-10-12-13-11-7;/h1-3H2,(H-,8,9,10,11,12,13);/q-1;+1
Molecular Formula | C7H8N6 |
Molecular Weight | 176.1786 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/18665582Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/21291763
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18665582
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/21291763
MK-0354 is a GPR109a (Niacin receptor 1) agonist, originated by Arena Pharmaceuticals. In phase II of clinical trials against dyslipidemia treatment with MK-0354 failed to produce changes in high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, or triglycerides.
Originator
Sources: https://adisinsight.springer.com/drugs/800020339
Curator's Comment: Drug was licensed by Arena Pharmaceuticals to Merk in 2006.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3785 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18665582 |
505.0 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
147 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21291763 |
1800 mg 2 times / day multiple, oral dose: 1800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
MK-0354 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
235 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21291763 |
1800 mg 2 times / day multiple, oral dose: 1800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
MK-0354 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
351 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21291763 |
3600 mg single, oral dose: 3600 mg route of administration: Oral experiment type: SINGLE co-administered: |
MK-0354 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
373 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21291763 |
3600 mg 1 times / day multiple, oral dose: 3600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
MK-0354 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
392 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21291763 |
1800 mg 2 times / day multiple, oral dose: 1800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
MK-0354 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
487 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21291763 |
1800 mg 2 times / day multiple, oral dose: 1800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
MK-0354 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
731 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21291763 |
3600 mg single, oral dose: 3600 mg route of administration: Oral experiment type: SINGLE co-administered: |
MK-0354 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
766 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21291763 |
3600 mg 1 times / day multiple, oral dose: 3600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
MK-0354 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21291763 |
1800 mg 2 times / day multiple, oral dose: 1800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
MK-0354 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
9.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21291763 |
1800 mg 2 times / day multiple, oral dose: 1800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
MK-0354 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
7.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21291763 |
3600 mg single, oral dose: 3600 mg route of administration: Oral experiment type: SINGLE co-administered: |
MK-0354 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
9.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21291763 |
3600 mg 1 times / day multiple, oral dose: 3600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
MK-0354 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
Title | Date | PubMed |
---|---|---|
3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice. | 2008 Aug 28 |
|
beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. | 2009 May |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21291763
In a phase II study MK-0354 was administred daily at dose 2.5g for 4 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18665582
Curator's Comment: Method was taken from reference 20 (https://www.ncbi.nlm.nih.gov/pubmed/15929991)
Equilibrium binding of [3H]nicotinic acid was done with membranes (30 μg/assay) from CHO-K1 cells, transfected with GPR109a, and test compound diluted in assay buffer (20 mM HEPES, pH 7.4, 1 mM MgCl2, and 0.01% CHAPS) in a total volume of 200 uL. After 4 h at room temperature, reactions were filtered through Packard Unifilter GF/C plates using a Packard Harvester and washed eight times with 200 μl of ice-cold binding buffer. Nonspecific binding was determined in the presence of 250 μM unlabeled nicotinic acid. Competitive binding assays were performed in the presence of 50 nM [3H]nicotinic acid.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:25:48 UTC 2023
by
admin
on
Fri Dec 15 15:25:48 UTC 2023
|
Record UNII |
LJM1M2YL86
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
LJM1M2YL86
Created by
admin on Fri Dec 15 15:25:48 UTC 2023 , Edited by admin on Fri Dec 15 15:25:48 UTC 2023
|
PRIMARY | |||
|
162623937
Created by
admin on Fri Dec 15 15:25:48 UTC 2023 , Edited by admin on Fri Dec 15 15:25:48 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|